Dyne Therapeutics Inc. (DYN)
undefined
undefined%
At close: undefined
25.73
-0.08%
After-hours Dec 13, 2024, 04:39 PM EST

Company Description

Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States.

It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.

The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..

Dyne Therapeutics Inc.
Dyne Therapeutics Inc. logo
Country United States
IPO Date Sep 17, 2020
Industry Biotechnology
Sector Healthcare
Employees 173
CEO John G. Cox M.B.A.

Contact Details

Address:
1560 Trapelo Road
Waltham, Massachusetts
United States
Website https://www.dyne-tx.com

Stock Details

Ticker Symbol DYN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001818794
CUSIP Number 26818M108
ISIN Number US26818M1080
Employer ID 36-4883909
SIC Code 2834

Key Executives

Name Position
John G. Cox M.B.A. Chief Executive Officer, President & Director
Amy Reilly Senior Vice President and Head of Corporate Communications & Investor Relations
Daniel Wilson Senior Vice President & Head of Legal
Debra Feldman Chief Regulatory Affairs Officer
Dr. Ashish Dugar M.B.A., Ph.D. Chief Medical Affairs Officer
Dr. Oxana Beskrovnaya Ph.D. Chief Scientific Officer
Dr. Romesh Subramanian Ph.D. Co-Founder & Advisor
John Najim M.B.A. Chief Technical Officer
Lucia Celona Chief Human Resource Officer
Richard William Scalzo M.B.A. Senior Vice President and Head of Finance & Administration

Latest SEC Filings

Date Type Title
Dec 11, 2024 4 Filing
Dec 11, 2024 4 Filing
Dec 10, 2024 4 Filing
Dec 06, 2024 4 Filing
Dec 06, 2024 4 Filing
Dec 06, 2024 4 Filing
Dec 06, 2024 4 Filing
Dec 06, 2024 4 Filing
Dec 06, 2024 4 Filing
Dec 04, 2024 4 Filing